As per the agreement, CML will buy three Sysmex HST-N total hematology automation systems and will implement them to meet core competencies in laboratory services and secure more clinical opportunities.

CML HealthCare president and CEO Thomas Wellner said Sysmex automated hematology lines will allow the company to increase capacity, improve operational efficiencies and reduce annual operating costs.

"In addition to its world-class technology, Sysmex is an ideal partner in providing a comprehensive set of resources and services including implementation, performance monitoring, and ongoing learning," Wellner added.

"We are proud to utilize Sysmex’s advanced clinical diagnostic tools to establish leading practices at our central laboratory to help us support the delivery of quality, timely, and cost-effective healthcare to Ontarians."

CML expects the Sysmex automated hematology lines to be fully implemented and operational in the company by the second quarter of 2013.